Urinary phenethylamine response to d-amphetamine in 12 boys with attention deficit disorder. 1984

A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt

Urinary phenethylamine (PEA), an endogenous amine similar to amphetamine in both molecular structure and pharmacological properties, was studied in 12 boys with attention deficit disorder with hyperactivity. d-Amphetamine and placebo were given for 14 days each in a counterbalanced crossover design; double-blind teacher behavior ratings and motor activity measurements were also obtained. Excretion of PEA, phenylacetic acid, creatinine, and d-amphetamine were measured. PEA was significantly increased and phenylacetic acid was unchanged after d-amphetamine administration, and change in PEA excretion correlated significantly with d-amphetamine excretion. There was no significant relationship between either clinical response to drug and change in PEA or phenylacetic acid excretion.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003913 Dextroamphetamine The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. d-Amphetamine,Curban,Dexamfetamine,Dexamphetamine,Dexedrine,Dextro-Amphetamine Sulfate,DextroStat,Dextroamphetamine Sulfate,Oxydess,d-Amphetamine Sulfate,dextro-Amphetamine,Dextro Amphetamine Sulfate,Sulfate, Dextroamphetamine,d Amphetamine,d Amphetamine Sulfate,dextro Amphetamine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
June 1983, Biological psychiatry,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
March 1999, Acta paediatrica (Oslo, Norway : 1992),
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
January 1991, The Journal of neuropsychiatry and clinical neurosciences,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
January 1994, Neuropsychobiology,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
December 1994, Perceptual and motor skills,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
December 2010, Journal of child and adolescent psychopharmacology,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
August 1985, Biological psychiatry,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
February 2006, Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
May 1984, Journal of the American Academy of Child Psychiatry,
A J Zametkin, and G L Brown, and F Karoum, and J L Rapoport, and D H Langer, and L W Chuang, and R J Wyatt
September 1999, Journal of clinical child psychology,
Copied contents to your clipboard!